Clinical Trial Update: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an alternative dosing schedule of palbociclib in metastatic hormone receptor-positive breast cancer has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Cancer, Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-03-15